Ardelyx shared its Q3 2026 results, showing $125.5 million in sales, up 19% from last year.

Nov 3, 2026, 5:17 PM ETResultsRead the original at Benzinga

Good for ARDX

Ardelyx’s two drugs grew sales in Q3, and the company reported $285.3 million in cash and expects to reach profit by 2027. Payer hurdles remain, but added support and rising sales make the outlook stronger.

ARDX · Ardelyx

AI read · Good for ARDX

The AI's read

Growth in both medicines supports Ardelyx’s business, and the company reports having cash and being on track to reach profit by 2027. Payer delays still make it harder for some patients to start IBSRELA, but Ardelyx has expanded reimbursement help and is exploring digital tools. Results from the IBS-C trial are not expected until the second half of 2027, so that possible growth remains unproven.

Get alerts for ARDX

Follow Ardelyx (ARDX) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for ARDX

Free on the App Store and Google Play, or on the web.